

CITATION REPORT

List of articles citing

Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration

DOI: 10.1016/0002-8703(87)90318-8
American Heart Journal, 1987, 114, 148-52.

Source: <https://exaly.com/paper-pdf/19126746/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
168	Short-term hemodynamic effects of intravenous methyldopa in patients with congestive heart failure. 1987 , 7, 216-22		10
167	Psychosocial stress and catecholamines: their relationship to ageing, duodenal ulcer, hypochondriasis and hypertension. 1988 , 63 Suppl 1, 24-6		2
166	Prognosis of congestive heart failure and predictors of mortality. 1988 , 62, 25A-30A		195
165	Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? III. Antagonist's viewpoint. 1988 , 12, 554-8		7
164	Current therapy of the failing heart. <i>Circulation</i> , 1988 , 78, 1099-107	16.7	93
163	Assessing cardiac pumping capability by exercise testing and inotropic stimulation. 1989 , 62, 20-5		25
162	Isoproterenol-induced alterations in myocardial blood flow, systolic and diastolic function in conscious dogs with heart failure. <i>Circulation</i> , 1989 , 80, 658-68	16.7	30
161	Prognostic factors affecting diagnosis and treatment of congestive heart failure. 1989 , 14, 625-71		13
160	Therapeutic progress--review XXXIV. Congestive cardiac failure. 1989 , 14, 1-19		2
159	Natural History and Prognosis of Overt Dilated Cardiomyopathy. 1990 , 337-346		4
158	Study population in SUPPORT: patients (as defined by disease categories and mortality projections), surrogates, and physicians. 1990 , 43 Suppl, 11S-28S		52
157	The maximal stress test: does it have any value in heart failure?. 1990 , 15, 62-3		3
156	Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. 1990 , 16, 1125-34		233
155	Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks. 1991 , 6, 393-401		
154	Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure. 1991 , 18, 1631-7		29
153	Crime, misdemeanor, and arrhythmia decoding CAST. 1991 , 31, 1044-52		1
152	Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure. 1991 , 67, 48C-52C; discussion 52C-54C		1

151	Sympathetic responses of patients with congestive heart failure to cold pressor stimulus. 1991 , 67, 993-1001	28
150	Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition. 1991 , 68, 121D-126D	17
149	The biochemical assessment of sympathoadrenal activity in man. 1991 , 1, 167-72	27
148	Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. <i>Circulation</i> , 1992 , 85, 942-9	16.7 175
147	Heart rate variations during isoproterenol infusion in congestive heart failure: relationships to cardiac mortality. <i>American Heart Journal</i> , 1992 , 123, 989-92	4.9 4
146	Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. 1992 , 70, 629-34	20
145	Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. 1992 , 69, 103-7	62
144	Effects of heart failure on baroreflex control of sympathetic neural activity. 1992 , 69, 523-31	174
143	Digitalis and neurohormonal abnormalities in heart failure and implications for therapy. 1992 , 69, 24G-32G; discussion 32G-33G	28
142	Digitalis and baroreflexes in heart failure. 1992 , 2, 21-6	2
141	Circadian rhythmicity of heart rate and QTc interval in diabetic autonomic neuropathy: implications for the mechanism of sudden death. <i>American Heart Journal</i> , 1993 , 125, 744-52	4.9 73
140	Sympathetic dysfunction in heart failure. 1993 , 7, 439-63	10
139	Seasonal mortality in the elderly. 1993 , 135-148	
138	Neurohormonal systems during progression of heart failure: a review. 1993 , 83, 21-9	18
137	Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. 1994 , 15, 454-61	33
136	Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and after heart transplantation. 1994 , 71, 422-30	97
135	Physiological rationale for co-treatment with diuretics in heart failure. 1994 , 72, S63-7	4
134	Prognosis in congestive heart failure. 1994 , 45, 341-50	43

133	Beta-blockers in cardiac failure. 1994 , 15 Suppl C, 16-24		7
132	Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. <i>Circulation</i> , 1994 , 89, 2843-51	16.7	41
131	Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure. 1994 , 8, 685-92		14
130	Neurohormones in patients with ischemic left ventricular dysfunction. 1994 , 8 Suppl 2, 313-7		4
129	Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. 1994 , 73, 488-93		87
128	Resting venous plasma adrenalin in 70-year-old men correlated positively to survival in a population study: the significance of the physical working capacity. 1994 , 235, 229-32		22
127	Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. 1994 , 24, 1678-87		273
126	Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. 1994 , 23, 1410-20		190
125	Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. 1994 , 23, 943-50		161
124	Abnormalities of contractile structures in viable myocytes of the failing heart. <i>International Journal of Cardiology</i> , 1994 , 43, 287-97	3.2	25
123	Idiopathic dilated cardiomyopathy. 1994 , 331, 1564-75		712
122	Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. 1994 , 4, 417-41		25
121	Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. 1994 , 15, 957-64		26
120	Effect of psychosocial stress and age on plasma norepinephrine levels: a review. 1994 , 56, 77-83		22
119	The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. 1995 , 16, 1613-8		100
118	Neural regulation of sympathetic nerve activity in heart failure. 1995 , 37, 397-414		134
117	Sympathetic dysregulation in heart failure: mechanisms and therapy. 1995 , 18, 13-8		40
116	Modulation of noradrenaline release through presynaptic alpha 2-adrenoceptors in congestive heart failure. <i>American Heart Journal</i> , 1995 , 130, 516-21	4.9	16

115	Sympathoadrenal activity and psychosocial stress. The significance of aging, long-term smoking, and stress models. 1995 , 771, 640-7		18
114	Evidence for reduction of norepinephrine uptake sites in the failing human heart. 1995 , 25, 146-53		191
113	Adverse consequences of high sympathetic nervous activity in the failing human heart. 1995 , 26, 1257-63		544
112	Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. 1996 , 77, 1197-201		19
111	Molecular Pathology of Dilated Cardiomyopathies. 1996 , 21, 99-144		6
110	Beta-blocker use in systolic heart failure and dilated cardiomyopathy. 1997 , 37, 7-19		19
109	Plasma beta-endorphin response to exercise in patients with congestive heart failure. 1997 , 111, 19-22		7
108	Status and prospect of current inotropic agents. 1997 , 7, 1297-1306		6
107	Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. <i>Journal of Nuclear Cardiology</i> , 1998 , 5, 579-90	2.1	142
106	Percent achieved of predicted peak exercise oxygen uptake and kinetics of recovery of oxygen uptake after exercise for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 1998 , 64, 117-24	3.2	25
105	Sympathetic Control of Circulation in Hypertension and Congestive Heart Failure. 1998 , 7, 40-45		6
104	ANG II and baroreflex function in rabbits with CHF and lesions of the area postrema. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999 , 277, H342-50	5.2	24
103	Enhanced activity of carotid body chemoreceptors in rabbits with heart failure: role of nitric oxide. 1999 , 86, 1273-82		116
102	Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. <i>Circulation Research</i> , 1999 , 84, 417-23	15.7	78
101	Beta-adrenergic receptors and receptor signaling in heart failure. 1999 , 39, 343-60		124
100	Heart Failure 99 -- the MOXCON story. <i>International Journal of Cardiology</i> , 1999 , 71, 109-11	3.2	58
99	Aerobic training involving a minor muscle mass shows greater efficiency than training involving a major muscle mass in chronic heart failure patients. 1999 , 5, 300-7		55
98	Age-adjusted heart rate variability as an index of the severity and prognosis of heart failure. 2000 , 64, 32-8		21

97	The control of adrenergic function in heart failure: therapeutic intervention. 2000 , 5, 101-14		30
96	The problem of ventricular dysrhythmias and sudden death mortality in heart failure: the impact of current therapy. 2000 , 93, 56-69		6
95	Increased plasma norepinephrine response to yohimbine in elderly men. 2000 , 55, M155-9		7
94	High urinary catecholamine excretion predicts mortality and functional decline in high-functioning, community-dwelling older persons: MacArthur Studies of Successful Aging. 2000 , 55, M618-24		39
93	Impairment of ventilatory efficiency in heart failure: prognostic impact. <i>Circulation</i> , 2000 , 101, 2803-9	16.7	280
92	Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. <i>American Heart Journal</i> , 2000 , 139, 587-95	4.9	39
91	The importance and complexity of neurohumeral over-activity in chronic heart failure. <i>International Journal of Cardiology</i> , 2000 , 73, 13-4	3.2	8
90	Beta-blockers - again, a lesson to us all, especially the research funding community. <i>International Journal of Cardiology</i> , 2000 , 73, 103-4	3.2	7
89	Chronic endothelin blockade in dogs with pacing-induced heart failure: possible modulation of sympathoexcitation. 2000 , 6, 56-65		21
88	Exercise and autonomic function in health and cardiovascular disease. <i>Cardiology Clinics</i> , 2001 , 19, 369-82.5		125
87	Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. <i>American Heart Journal</i> , 2001 , 141, 645-52	4.9	66
86	Endogenous angiotensin II in the NTS contributes to sympathetic activation in rats with aortocaval shunt. 2001 , 280, R1665-73		23
85	Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. 2001 , 280, R1906-13		40
84	Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy. 2001 , 85, 692-6		9
83	Comprehensive local muscle training increases aerobic working capacity and quality of life and decreases neurohormonal activation in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 47-52	12.3	89
82	beta-Blocker therapy in heart failure: scientific review. 2002 , 287, 883-9		226
81	Acute effect of endothelin AB antagonist on sympathetic outflow in conscious rats with heart failure. 2002 , 66, 841-5		7
80	Treatment of heart failure in patients with diabetes mellitus. 2002 , 62, 285-307		5

79	[Prognostic value of cytokines and neurohormones in severe heart failure]. 2002 , 55, 481-6		13
78	Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure. 2002 , 22, 261-8		4
77	MIBG imaging. <i>Journal of Nuclear Cardiology</i> , 2002 , 9, 75-94	2.1	76
76	AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease. 2003 , 23, 285-96		25
75	Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. 2003 , 9, 113-21		24
74	The aminotetraline derivative (+/-)-(R,S)-5,6-dihydroxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene hydrochloride (CHF-1024) displays cardioprotection in postischemic ventricular dysfunction of the rat heart. 2003 , 307, 633-9		6
73	Decreased facilitation by angiotensin II of noradrenergic neurotransmission in isolated mesenteric artery of rabbits with chronic heart failure. 2003 , 41, 356-62		6
72	Drug development and the importance of ethnicity: lessons from heart failure management and implications for hypertension. 2004 , 10, 3569-77		3
71	Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. <i>Circulation Research</i> , 2004 , 94, 402-9	15.7	122
70	Heart failure--the importance of ethnicity. <i>European Journal of Heart Failure</i> , 2004 , 6, 831-43	12.3	19
69	BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. 2004 , 5, 121-9		20
68	Autonomic receptor systems in the failing and aging human heart: similarities and differences. <i>European Journal of Pharmacology</i> , 2004 , 500, 167-76	5.3	57
67	Neurohumorale Reaktion unter Schrittmachertherapie. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2004 , 15, i1	0.8	
66	Iodine 123-metaiodobenzylguanidine imaging reflect generalized sympathetic activation in patients with left ventricular dysfunction. <i>Clinical Physiology and Functional Imaging</i> , 2005 , 25, 34-9	2.4	8
65	Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 289, H2159-66	5.2	22
64	Endothelin receptor antagonists. 2006 , 110, 386-414		136
63	Correlation between activation of the sympathetic nervous system estimated by plasma concentrations of norepinephrine and Doppler echocardiographic variables in dogs with acquired heart disease. <i>American Journal of Veterinary Research</i> , 2006 , 67, 1163-8	1.1	7
62	Effects of Carvedilol Treatment in Dogs with Chronic Mitral Valvular Disease. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 996-1001	3.1	11

61	Diagnostic and prognostic value of BMIPP imaging. <i>Journal of Nuclear Cardiology</i> , 2007 , 14, 111-25	2.1	10
60	Activation of Rho-kinase in the brainstem enhances sympathetic drive in mice with heart failure. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2008 , 142, 77-81	2.4	15
59	Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. <i>European Journal of Heart Failure</i> , 2008 , 10, 1186-91	12.3	35
58	Carvedilol in the treatment of elderly patients with chronic heart failure. <i>Clinical Interventions in Aging</i> , 2008 , 3, 55-70	4	1
57	Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload. <i>Circulation Research</i> , 2009 , 104, 1004-11	15.7	30
56	Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. <i>Current Vascular Pharmacology</i> , 2009 , 7, 137-45	3.3	31
55	Cardiac metaiodobenzylguanidine imaging and heart failure. <i>Current Heart Failure Reports</i> , 2013 , 10, 359-64	2.8	4
54	Quantitative 123I-MIBG SPECT/CT assessment of cardiac sympathetic innervation--a new diagnostic tool for heart failure. <i>International Journal of Cardiology</i> , 2013 , 168, 1556-8	3.2	6
53	The Renaissance era of sympathomodulatory interventions in the treatment of hypertension-related congestive heart failure. <i>Journal of Hypertension</i> , 2013 , 31, 2133-5	1.9	
52	Renal denervation: a novel non-pharmacological approach in heart failure. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 330-7	3.3	5
51	Renal denervation and heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 608-13	12.3	44
50	Renal denervation: effects on atrial electrophysiology and arrhythmias. <i>Clinical Research in Cardiology</i> , 2014 , 103, 765-74	6.1	32
49	Autonomic Innervation of the Heart. 2015 ,		2
48	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. <i>International Journal of Cardiology</i> , 2015 , 191, 256-64	3.2	94
47	Interventional Therapies for Secondary and Essential Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016 ,	0.1	
46	[Baseline characteristics and changes in treatment after a period of optimization of the patients included in the study EFICAR]. <i>Atencion Primaria</i> , 2016 , 48, 166-74	3.6	
45	Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: A Prospective, Randomized, Controlled, Pilot Study. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E153-E161	2.7	28
44	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. <i>Korean Circulation Journal</i> , 2017 , 47, 9-15	2.2	8

43	Measurement of plasma norepinephrine and 3,4-dihydroxyphenylglycol: method development for a translational research study. <i>BMC Research Notes</i> , 2018 , 11, 248	2.3	10
42	Combined Evaluation of the Plasma Arginine Vasopressin and Noradrenaline Levels May be a Useful Predictor of the Prognosis of Patients with Acute Decompensated Heart Failure. <i>International Heart Journal</i> , 2018 , 59, 791-801	1.8	7
41	Palliative care in end-stage heart failure: experience of a collaborative approach in a secondary care setting. <i>Internal Medicine Journal</i> , 2019 , 49, 404-407	1.6	
40	Sympathomodulation in congestive heart failure: From drugs to devices. <i>International Journal of Cardiology</i> , 2020 , 321, 118-125	3.2	2
39	An Injectable Microparticle Formulation Provides Long-Term Inhibition of Hypothalamic ERK1/2 Activity and Sympathetic Excitation in Rats with Heart Failure. <i>Molecular Pharmaceutics</i> , 2020 , 17, 3643-3648	5.6	1
38	Metrics of High Cofluctuation and Entropy to Describe Control of Cardiac Function in the Stellate Ganglion.		
37	Neurohormonal Responses in Congestive Heart Failure: Effect of Ace Inhibitors in Randomized Controlled Clinical Trials. <i>Developments in Cardiovascular Medicine</i> , 1995 , 487-501		1
36	Overview of Pathophysiology of Clinical Heart Failure. 1994 , 11-16		3
35	Pathophysiology and Clinical Recognition of Heart Failure. 2007 , 1379-1396		1
34	Neurohumoral Aspects of Heart Failure. <i>Cardiology Clinics</i> , 1994 , 12, 9-23	2.5	27
33	Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. <i>Circulation</i> , 1995 , 92, 3206-11	16.7	290
32	Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. <i>Circulation</i> , 1995 , 92, 1191-5	16.7	129
31	Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. <i>Circulation</i> , 1997 , 96, 1173-9	16.7	142
30	Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. <i>Hypertension</i> , 1995 , 26, 719-24	8.5	56
29	Angiotensin II blockade [corrected] enhances baroreflex control of sympathetic outflow in heart failure. <i>Hypertension</i> , 1997 , 29, 564-9	8.5	54
28	Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure. <i>EuroIntervention</i> , 2013 , 9 Suppl R, R122-6	3.1	7
27	Akute kardiale Dyspnoe und Lungenödem. 2000 , 527-538		
26	Pathophysiologie der chronischen Herzinsuffizienz. 2000 , 545-595		

- 25 Klinik und Symptomatologie der chronischen Herzinsuffizienz. **2000**, 597-610
- 24 Dilatative Kardiomyopathie (DCM) Morphologie und Biologie. Myokarditis und DCM. *Spezielle Pathologische Anatomie*, **2000**, 929-1053
- 23 Definition und Epidemiologie der chronischen Herzinsuffizienz. **2000**, 539-543
- 22 Prognostic Indicators and Assessment of Therapeutic Responses. **2002**, 145-159
- 21 Evaluation of Sympathetic Nerve Function in Patients with Heart Failure by MIBG Myocardial Scintigraphy. *Advances in Behavioral Biology*, **2002**, 495-498
- 20 Kardiomyopathien. **2003**, 99-114
- 19 Sympathetic Interactions of AT1 Receptors. *Handbook of Experimental Pharmacology*, **2004**, 351-372 3,2
- 18 Herzinsuffizienz. **2004**, 323-366
- 17 Guidelines for Improving Prognosis, Stress Tolerance, and Quality of Life in Patients with Heart Failure: Cardiological and Psychological Aspects. **1991**, 118-131
- 16 Perioperative Management of Patients with Compromised Left and Right Ventricular Function. *Anesthesiology Clinics*, **1991**, 9, 637-656 1
- 15 Clinical experience with iodine-123 metaiodobenzylguanidine. *Developments in Cardiovascular Medicine*, **1992**, 387-397
- 14 Pathophysiologie Adrenerges System: kardiale adrenerge Rezeptoren und Signaltransduktionssysteme. *Aktuelle Therapieprinzipien in Kardiologie Und Angiologie*, **1992**, 139-156
- 13 Congestive Heart Failure: Acute and Chronic. **1992**, 365-381
- 12 Alterations of the Sympathetic Nervous System in Heart Failure. **1994**, 293-314
- 11 Herzinsuffizienz. **1996**, 421-474
- 10 Calciumantagonisten bei chronischer Herzinsuffizienz. **1996**, 311-323
- 9 Literatur. **1997**, 105-118
- 8 Molekulare Grundlagen der Herzinsuffizienz. **1998**, 147-221 0

- 7 Nuclear Cardiology 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging. **2015**, 463-528
- 6 Imaging Sympathetic Innervation of the Heart: Therapeutic Strategies SPECT/CT and PET/CT. **2015**, 367-385
- 5 Renal Denervation for Chronic Heart Failure. *Updates in Hypertension and Cardiovascular Protection*, **2016**, 281-292 0.1
- 4 Kardiomyopathien. **2007**, 173-190
- 3 Basis of Cardiac Imaging 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging in Coronary Artery Disease and Congestive Heart Failure. **2006**, 352-394
- 2 A review of ethical considerations for ventricular assist device placement in older adults. **2013**, 4, 100-12 5
- 1 Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure.. *Clinical Research in Cardiology*, **2022**, 1 6.1 0